The Future of Diffuse Large B-Cell Lymphoma (DLBCL) Treatment: Insights from Global Research
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, shares new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL), further reinforcing its leadership in oncology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241115682139/en/
DLBCL is the most prevalent and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for 30-40% of cases worldwide. Its heterogeneity, characterized by key subtypes like Germinal Center B-cell (GCB) and Activated B-cell (ABC), poses significant challenges in treatment. Novotech’s latest analysis highlights these complexities while highlighting ongoing advancements in therapeutic strategies to address this aggressive disease.
Key Insights from DLBCL Clinical Trials
Since 2019, more than 1,500 clinical trials for DLBCL have been initiated globally, indicating strong research momentum:
- Asia-Pacific: Leads with 41% of trials, driven largely by China’s clinical research activity.
- North America: Accounts for 33% of trials, with the United States leading in trial volume.
- Europe: Represents 19% of trials, focusing on both hematological and solid tumor research.
These findings highlight the global effort to improve treatment options for DLBCL patients.
Advances in DLBCL Treatment
Novotech’s report also highlights breakthroughs in DLBCL treatment, moving beyond traditional chemotherapy to explore new therapeutic options:
- Targeted therapies: Phase III trials for Mosunetuzumab and Selinexor are showing promise, particularly for relapsed or refractory DLBCL patients.
- Immunotherapies: Novotech is involved in the development of CAR T-cell therapies, checkpoint inhibitors, and bispecific antibodies, which have shown strong efficacy in high-risk DLBCL patients who do not respond to standard treatments like R-CHOP.
Ongoing efforts to personalize DLBCL treatment through genomic profiling and molecular diagnostics are expected to yield more precise and effective treatment strategies. In combination with innovative therapies such as EZH2 inhibitors targeting GCB subtypes and novel agents addressing the ABC subtype, these approaches are advancing more tailored and successful interventions.
Download the Full Report
For detailed analysis of the DLBCL clinical trial landscape, including emerging treatment strategies and global trial trends, download Novotech’s latest DLBCL Global Clinical Trial Landscape Report.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost &Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241115682139/en/
Contacts
Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 202523.5.2025 00:43:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers. “The new clinical data we are presenting at ASCO showcase our dedication to advancing innovative therapies for a wide range of diseases—spanning from common cancers to rare non-malignant neoplasms,” said Victoria Zazulina, M.D., Head of Development Unit, Oncology, for the Healthcare business of Merck. “From encouraging early data for our lead antibody-drug conjugate, precemtabart tocentecan, in patients with advanced CRC, to new Phase
Cooperation between Topcon Positioning Systems and Amberg Technologies Ltd.22.5.2025 23:17:00 EEST | Press release
Topcon Positioning Systems and Amberg Technologies Ltd. have initiated a close collaboration to enable interoperability between Topcon’s sensor solutions and Amberg Technologies’ software and hardware platforms for rail and tunnel applications. This marks the first step towards offering fully integrated solutions to our shared customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522363239/en/ Luc Le Maire, Senior Vice President, Topcon (left) and Johannes Mueller, CEO, Amberg Technologies. About Topcon Positioning Systems Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, X, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Cor
LBT Holdings Ltd. Acquires Gonet Bank & Trust Limited, Introducing Bank of Nassau to Uphold the Finest Traditions of Private Banking22.5.2025 19:29:00 EEST | Press release
LBT Holdings Ltd., in partnership with Gonet SA, is pleased to announce the successful acquisition of Gonet Bank & Trust Limited, a distinguished Bahamas-based private bank formerly owned by Gonet SA. The transaction, which has received full regulatory approval from the Swiss Financial Market Supervisory Authority (FINMA), the Central Bank of The Bahamas (CBOB), and The Securities Commission of The Bahamas (SCB), marks a significant milestone for both organizations. Effective immediately, LBT Holdings Ltd. assumes 100% ownership of Gonet Bank & Trust Limited. As part of this strategic transition, Gonet Bank & Trust Limited will be rebranded as Bank of Nassau 1982 Limited, reflecting its renewed vision and commitment to excellence in private banking and wealth management. This acquisition strengthens the position of all parties in the global financial services sector, enabling expanded service offerings while upholding the highest standards of client-centric banking. Bank of Nassau 1982
PPG highlights continued progress toward 2030 sustainability targets in latest report22.5.2025 16:31:00 EEST | Press release
PPG (NYSE:PPG) today announced continued progress against its near-term 2030 sustainability targets, including reducing greenhouse gas (GHG) emissions throughout its own operations and value chain, and continued improvement in sustainably advantaged product sales driven by customer demand. “Sustainability is core to our purpose and a key enabler of our enterprise growth strategy,” said Peter Votruba-Drzal, PPG vice president, global sustainability. “It is embedded in how we do business by supporting our customers’ success through sustainably advantaged solutions that deliver industry-leading products, improved performance and operational savings, resulting in reduced water, waste and energy use.” Key highlights in PPG’s 2024 Sustainability Report include: 41% of sales from sustainably advantaged products, such as the PPG ENVIRO-PRIME® EPIC200X solution, which enabled a customer’s facility to reduce CO2 emissions by 3,500 metric tons annually. Significant expansion in renewable energy e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom